(Date:11/30/2009)...Newswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVA... the Phase II clinical study of its trivalent seas... vaccine candidate in healthy adults 60 years of a...le-blind, active-controlled study is comparing the...fferent doses (15 mcg and 60 mcg) of Novavax,s tri...
(Date:11/30/2009)...PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ),...cal-device research and,development outsourcing co...es,announced that it had been selected to the Del...ifth consecutive year. The list recognizes the 50,...edia, and telecommunications,industries based on r...
(Date:11/27/2009)... Cromoz Inc., located in Research T...anotube-based cancer drug delivery system in Hyder...hich have functional groups on the walls that allo...d in partnership with the Indian Institute of Kanp...s a drug delivery vehicle with the ability to targ...
(Date:11/25/2009)...swire/ -- Biotech firm Replikins Ltd., which has a... pandemic through the prediction, outbreak, and pr...its latest biochemical analysis of the virus. The ...ine Flu") virus has dropped from its peak of 3.7 (...he spring of 2009 to resting non-epidemic levels t...
Breaking Biology Technology:NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5...LE, Virginia, April 2 Biovista Inc. today,announc...osis (MS), has shown,significant positive results ...myelitis (EAE) murine model of MS. BVA-101, an exi... aimed at neuroprotection, was shown to,have both ... in this well,established model of MS. , "We a...
... 2 Nuevolution A/S today announced that Merck &am...ase of the collaboration agreement announced in Ju...cs(R) drug discovery technology to identify novel ... , , By entering the second phase, Merck gains ac...rary of small molecule drug candidates. In additi...
..., April 1 On April 1, 2009, Xmark Opportunity Par...ger of Xmark Opportunity Fund, L.P. and Xmark Oppo...he Board of Directors of Icagen, Inc. (Nasdaq: I...UNITY PARTNERS, LLC, ... Suite 201, ...
Other Biology Technology:Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis 2Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc. 2Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign 2Mouse Anti-CKII beta Monoclonal Antibody, Unconjugated from Abcam
...ased selection system for recombinant identificati... survival, eliminating the need for costly color s...des close to 100% accuracy in recombinant selectio... colony picking. This cloning kit is customized a...
Anti-Poly (ADP-Ribose) Polymerase from Roche Applied Science
F40 Pump Maintenance Kit from Bio-Rad
Biology Products: